Correlation Between Medigen Biotechnology and Huang Hsiang

Can any of the company-specific risk be diversified away by investing in both Medigen Biotechnology and Huang Hsiang at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Medigen Biotechnology and Huang Hsiang into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Medigen Biotechnology and Huang Hsiang Construction, you can compare the effects of market volatilities on Medigen Biotechnology and Huang Hsiang and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Medigen Biotechnology with a short position of Huang Hsiang. Check out your portfolio center. Please also check ongoing floating volatility patterns of Medigen Biotechnology and Huang Hsiang.

Diversification Opportunities for Medigen Biotechnology and Huang Hsiang

-0.6

Correlation Coefficient

Medigen Biotechnology  Huang Hsiang

Excellent diversification

The 3 months correlation between Medigen and Huang is -0.6. Overlapping area represents the amount of risk that can be diversified away by holding Medigen Biotechnology and Huang Hsiang Construction in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Huang Hsiang Construction and Medigen Biotechnology is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Medigen Biotechnology are associated (or correlated) with Huang Hsiang. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Huang Hsiang Construction has no effect on the direction of Medigen Biotechnology i.e., Medigen Biotechnology and Huang Hsiang go up and down completely randomly.

Pair Corralation between Medigen Biotechnology and Huang Hsiang

Assuming the 90 days trading horizon Medigen Biotechnology is expected to generate 0.5 times more return on investment than Huang Hsiang. However, Medigen Biotechnology is 2.0 times less risky than Huang Hsiang. It trades about -0.17 of its potential returns per unit of risk. Huang Hsiang Construction is currently generating about -0.15 per unit of risk. If you would invest  3,435  in Medigen Biotechnology on September 20, 2024 and sell it today you would lose (235.00) from holding Medigen Biotechnology or give up 6.84% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Weak
Accuracy	100.0%
Values	Daily Returns

Medigen Biotechnology  vs.  Huang Hsiang Construction

Medigen Biotechnology

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Medigen Biotechnology has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of abnormal performance in the last few months, the Stock's basic indicators remain fairly stable which may send shares a bit higher in January 2025. The latest fuss may also be a sign of long-term up-swing for the venture sophisticated investors.

Huang Hsiang Construction

Risk-Adjusted Performance

3 of 100

Very Weak

Compared to the overall equity markets, risk-adjusted returns on investments in Huang Hsiang Construction are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. In spite of fairly abnormal basic indicators, Huang Hsiang may actually be approaching a critical reversion point that can send shares even higher in January 2025.

Pair Trading with Medigen Biotechnology and Huang Hsiang

The main advantage of trading using opposite Medigen Biotechnology and Huang Hsiang positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Medigen Biotechnology position performs unexpectedly, Huang Hsiang can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Huang Hsiang will offset losses from the drop in Huang Hsiang's long position.

The idea behind Medigen Biotechnology and Huang Hsiang Construction pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.